source
- Vertex, ahead of FDA decision, calms fears surrounding kidney drugOn a conference call, executives expressed conviction in the coming launch of an IgA nephropathy medicine viewed by Wall Street investors as important to Vertex’s future.
- FDA sets May 1 decision date for uniQure's Huntington's disease gene therapy after year-long regulatory sagaThe U.S. Food and Drug Administration has accepted uniQure's biologics license application for its Huntington's disease gene therapy and placed it on the priority review track, with a May 1 target…